CD8A and neoplasm: Correspondingly, the above CD8+ T cells that were activated by the BMDCs from DOX@3D-MPs-treated group evoked the strongest cytotoxicity against the respective H22, 4T1 or B16-OVA cells (Fig. 3l and Supplementary Figs. 9l and 10g), confirming that DOX@3D-MPs-triggered ICD efficiently activate tumor-specific CD8+ T cells to elicit antitumor immune response.